What type of study is this?

This is a Pre-Registered Trial study.

What question did this study set out to answer?

This research aims to analyze the impact of daratumumab combined with lenalidomide on minimizing residual disease in multiple myeloma patients post-transplant.

December 8, 2025Blood

Minimal residual disease dynamics in post-transplant patients with newly diagnosed multiple myeloma who received daratumumab plus lenalidomide versus lenalidomide alone as maintenance therapy in the auriga study

View Full Paper

Ask AI

Bookmark

Authors

ACAlfred Chung LALarry J. Anderson LFLaahn Foster

Discussion

Member takes

Overview

Phase 3 trial shows daratumumab plus lenalidomide improves MRD rates in multiple myeloma, suggesting enhanced treatment outcomes.

Key Points

This research aims to analyze the impact of daratumumab combined with lenalidomide on minimizing residual disease in multiple myeloma patients post-transplant.
Phase 3 AURIGA study with randomized patients post-autologous stem cell transplant
Eligible patients received either lenalidomide maintenance alone or with daratumumab.
MRD dynamics and conversion rates were assessed using NGS at multiple time points.
Daratumumab plus lenalidomide led to a 60.6% MRD-neg conversion rate versus 28.7% for lenalidomide alone.
Sustained MRD-neg rates at 10−5 were 29.3% for the combination vs 7.9% for lenalidomide alone.
Fewer patients with MRD-neg conversion experienced disease recurrence compared to those with residual disease.

Cite This Study

Chung et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236d055 https://doi.org/10.1182/blood-2025-97

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

Minimal residual disease dynamics in post-transplant patients with newly diagnosed multiple myeloma who received daratumumab plus lenalidomide versus lenalidomide alone as maintenance therapy in the auriga study

View Full Paper

Ask AI

Bookmark

Authors

ACAlfred Chung LALarry J. Anderson LFLaahn Foster

Discussion

Member takes

Overview

Phase 3 trial shows daratumumab plus lenalidomide improves MRD rates in multiple myeloma, suggesting enhanced treatment outcomes.

Key Points

This research aims to analyze the impact of daratumumab combined with lenalidomide on minimizing residual disease in multiple myeloma patients post-transplant.
Phase 3 AURIGA study with randomized patients post-autologous stem cell transplant
Eligible patients received either lenalidomide maintenance alone or with daratumumab.
MRD dynamics and conversion rates were assessed using NGS at multiple time points.
Daratumumab plus lenalidomide led to a 60.6% MRD-neg conversion rate versus 28.7% for lenalidomide alone.
Sustained MRD-neg rates at 10−5 were 29.3% for the combination vs 7.9% for lenalidomide alone.
Fewer patients with MRD-neg conversion experienced disease recurrence compared to those with residual disease.

Cite This Study

Chung et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236d055 https://doi.org/10.1182/blood-2025-97

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark